Aspen on track to meet its debt targets, says CEO Stephen Saad
Saad says SA’s biggest pharmaceutical manufacturer is still on the hunt for a potential European commercial partner
11 November 2019 - 18:00
SA’s biggest pharmaceutical manufacturer Aspen Pharmacare says it is on track to meet its debt reduction targets by the end of its financial year, after agreeing to sell its Japanese business to Novartis’s generic division Sandoz for as much as €400m (R6.5bn).
It has also entered into a five-year manufacturing and supply agreement with Sandoz for the portfolio of divested brands...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.